THE DEAL, AT A GLANCE

Sling Therapeutics

2/4 reviewed

Sling Therapeutics

Sling develops linsitinib, an oral treatment being tested for thyroid eye disease.

Sling Therapeutics raised $123M Series C, announced 2026-09-16

01What it doesSling develops linsitinib, an oral treatment being tested for thyroid eye disease.Source-grounded · automated review · Explore ↗

Checked 2026-10-06 · Review due 2026-10-13

Read supporting source ↗

Our lead pipeline program, linsitinib,…

02What happenedSling Therapeutics raised $123M Series C, announced 2026-09-16From the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗

03Why it mattersThe company targets a convenient pill option for thyroid eye disease patients.Interpretation · Explore ↗

Checked 2026-10-06 · Review due 2026-10-13

Read supporting source ↗

At Sling, we’re on a…

Click a part to explore its evidence. The image is supplied by the cited source.Original record source ↗

Sling Therapeutics · Financing Record

Explore source-linked visual explanations for Sling Therapeutics. Unsupported claims are withheld while source review continues.

Record 12427 · Recorded date: 2026-09-16